Commentary: Gastrointestinal safety of coxibs and outcomes studies: What's the verdict?

Journal of Pain and Symptom Management

Volumn 23, Issue 4 SUPPL. 1, 2002, Pages

  Bjorkman, David J ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Celecoxib; COX 2 specific inhibitors; Coxibs; Gastrointestinal; Nonsteroidal anti inflammatory drugs; Rofecoxib; Safety; Ulcers

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; MISOPROSTOL; PROSTAGLANDIN; PROTON PUMP INHIBITOR; ROFECOXIB;

ANALGESIA; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL TRACT; HUMAN; INCIDENCE; OUTCOMES RESEARCH; RISK FACTOR; TOXICITY; ULCER;

EID: 0036248045     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(02)00369-X     Document Type: Conference Paper

References (19)

1. History of aspirin and its mechanism of action
2. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs
3. Damage to the gastric mucosa: Effects of salicylates and stimulation
4. Aspirin and NSAIDs: Mechanisms of action
5. Identification of a phorbol ester-repressible v-src-inducible gene
6. Biochemistry of prostaglandin endoperoxide H synthase-1 and synthase-2 and their differential susceptibility to nonsteroidal anti-inflammatory drugs
7. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs
8. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs
9. NSAIDs, gastrointestinal injury, and cytoprotection
10. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs
11. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs
12. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs
13. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group
14. Comparison of the effect of rofecoxib (a cyclooxygenase-2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group
15. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
16. Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: Risk factors and frequency of complications
17. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
18. Gastrointestinal safety of coxibs and outcomes studies: What's the verdict?